Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03521960 · ClinicalTrials.gov registry record · Phase 1
Buspirone for Opioid Tapering
A Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT03521960: Completed Phase 1 study, sponsored by Johns Hopkins University.
NCT03521960 is a Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03521960, a Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a pilot study to collect preliminary data to support a grant application. The goal of the study is to evaluate whether the Food and Drug Administration (FDA)-approved and generically-available medication buspirone reduces symptoms of opioid withdrawal among patients undergoing a clinically-indicated and supervised taper from their opioid pain medications. This is premised on strong preclinical scientific support but has not yet be well-examined in humans.
Interventions
- DRUG Placebo oral capsule
- DRUG Buspirone oral capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-05-30 |
| Est. Completion | 2020-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03521960
The ClinicalTrials.gov registry entry for NCT03521960 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03521960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03521960 about?
NCT03521960 is a clinical study titled "Buspirone for Opioid Tapering". This is a pilot study to collect preliminary data to support a grant application. The goal of the study is to evaluate whether the Food and Drug Administration (FDA)-approved and generically-available medication buspirone reduces symptoms of opioid withdrawal among patients undergoing a clinically-i...
What is the current status of trial NCT03521960?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2018-05-30. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT03521960?
The interventions under investigation include: Placebo oral capsule (DRUG), Buspirone oral capsule (DRUG).
Who is sponsoring clinical trial NCT03521960?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.